Cereno Scientific‘s investigational therapy CS1 was well tolerated and showed signs of clinical benefit in people with pulmonary arterial hypertension (PAH), according to top-line data from a Phase 2a clinical trial. The company plans to start discussions with regulatory authorities and will pursue a pivotal clinical trial to…
Elevated blood levels of uric acid are associated with a higher risk of pulmonary arterial hypertension (PAH) at the genetic level, a data study reported. “Overall, this study confirmed, from a genetic perspective, the causal relationship between serum UA [uric acid] levels and PAH,” the researchers wrote. They also…
Cereno Scientific’s investigational therapy CS014 was found to reverse remodeling, meaning alterations in structure and arrangement, of pulmonary arteries in a preclinical model of pulmonary arterial hypertension (PAH). According to the company, the new preclinical data “provide the most compelling evidence to date that CS014 offers a…
Differences in Uptravi (selexipag) maintenance doses have no impact on the risk of hospitalization among adults with pulmonary arterial hypertension (PAH), a real-world claims analysis suggests. While different maintenance doses did not affect treatment adherence or discontinuations among U.S. patients in the real world, dose adjustments were more…
Oral carnitine supplements were well tolerated and blood levels of the molecule increased in people with pulmonary arterial hypertension (PAH), a pilot study shows. Carnitine transports fatty acids — the building blocks of fatty molecules…
Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…
Having fewer very fine blood vessels in the fold of skin at the base of the fingernails appears to be linked to an increased risk of clinical worsening in pulmonary arterial hypertension (PAH), a study in the Netherlands suggests. People with chronic thromboembolic pulmonary hypertension (CTEPH) also had…
The Pulmonary Hypertension Association (PHA) will host two events the last weekend of October to raise awareness about pulmonary hypertension (PH), seek funding, and support the PH community in anticipation of PH Awareness Month, which happens every…
Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a Phase 1 clinical trial. This reduction in pulmonary vascular resistance (PVR) is one of the highest seen in PH…
Tyvaso (inhaled treprostinil) appears to be well tolerated by patients with different types of pulmonary hypertension (PH), and stopping the treatment increases the risk of disease worsening, a study found. The study, “Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil,”…
Ten members of the pulmonary hypertension (PH) community were honored by the Pulmonary Hypertension Association (PHA) for their dedication and service. The Outstanding Member Awards ceremony took place Aug. 17 at the PHA 2024 International PH Conference and Scientific Sessions in Indianapolis. The awards honor people who’ve shown exceptional dedication…
Health Canada has approved Merck’s Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension (PAH). The approval specifically covers the use of Winrevair in combination with standard therapies to treat patients with World Health Organization (WHO) functional classification 2 or 3. The decision follows approvals in the U.S., as…
Get regular updates to your inbox.